Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -1.16% 42.50p 41.00p 44.00p 43.00p 42.50p 43.00p 44,308 08:20:58
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.5 -7.4 -8.7 - 49.76

Angle Share Discussion Threads

Showing 47351 to 47375 of 47375 messages
Chat Pages: 1895  1894  1893  1892  1891  1890  1889  1888  1887  1886  1885  1884  Older
DateSubjectAuthorDiscuss
24/11/2017
12:24
What's the income generation like?
boris cobaka
23/11/2017
11:55
Excellent news to be at the heart of the project. All long term value building and confirmation from a 2nd major company that Parsortix is the tech of choice. The share price has been very solid since the raise and I'm fairly sure we have some II's accumulating shares. It might take a bit longer to break back into much higher territory (ie 60's) until any overhang from the placing clears, but it will be clear once it does! Still expect an opportunistic bid at some point.
waterloo01
23/11/2017
09:40
Thanks for the info and link Bermuda.
maxie23
23/11/2017
09:32
Thanks Bermuda.
semper vigilans
23/11/2017
09:30
More on the LIMA project below. Note that it complements the Cancer-ID project. Angle were selected for the Cancer-ID project back in Feb. Building blocks being put in place and starting to yield results. hTTps://european-biotechnology.com/up-to-date/latest-news/news/philips-lead-eur63m-eu-liquid-biopsy-consortium.html
bermudashorts
23/11/2017
09:11
Any stock about?
semper vigilans
23/11/2017
08:53
I see AGL is also getting additional funding for this collaboration. Starting to look like the market will never understand AGL and it is one of those stocks which needs to be taken over and developed as part of a larger group.
alloa2003
23/11/2017
08:36
List of recent acquisitions below - not sure how this scenario would fit in with Qiagen though. hxxps://www.philips.com/a-w/about/investor/capital-reallocation/acquisitions.html
bermudashorts
23/11/2017
08:26
Getting harder to knock the progress. Philips would have done a great deal of DD to ensure none of the partners listed on this project might be a weak link that undermines the chances of success. Anyone know if Philips are acquisitive, they might fancy grabbing the technology if they like what they see...just not yet please :)
yamba
23/11/2017
08:21
Great news. Eventually this unrealistic share price will spread it's wings and fly.
maxie23
23/11/2017
08:15
Very pleasing :-)
oiht
23/11/2017
07:56
Adoption for this study must also put more evidence behind the FDA submission.
semper vigilans
23/11/2017
07:31
This is excellent news. If you look back at the RNS's released over the last 2 or 3 months, there really has been significant news flow with 2 multi-billion dollar companies (Qiagen and Philips) forming partnerships with Angle - tremendous validation for the Parsortix system. Worth noting this line from today's RNS:- "We look forward to joint commercialisation of these solutions and to working closely with Philips going forward. " hTTps://www.philips.co.uk/healthcare/medical-specialties/oncology
bermudashorts
23/11/2017
07:22
A bit more European Research Funding for us too.
4legs
23/11/2017
07:11
Yes Willy, and with a substantial partner.
semper vigilans
23/11/2017
07:11
Like this bit...Philips has selected ANGLE's ParsortixTM system as the sole system to be used for harvesting circulating tumor cells (CTCs) for analysis in the research collaboration, which is an important area of development for Philips following its restructuring in 2016 to focus on healthcare.
willfy
23/11/2017
07:10
Another good RNS with tie up with Philips
4legs
23/11/2017
07:09
Excellent news of another collaboration
willfy
23/11/2017
07:09
Nice one. This sort of recognition from a company like Philips is priceless. RNS Number : 2918X Angle PLC 23 November 2017 For immediate release 23 November 2017 ANGLE plc ("the Company") COLLABORATION WITH PHILIPS IN BREAST AND RECTAL CANCER ANGLE to receive European research grants of £0.4 million ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that it has established a collaboration with Philips to develop liquid biopsy solutions. Philips has successfully secured a European Union research grant worth €6.3 million, of which £0.4 million will flow to ANGLE. Philips has selected ANGLE's ParsortixTM system as the sole system to be used for harvesting circulating tumor cells (CTCs) for analysis in the research collaboration, which is an important area of development for Philips following its restructuring in 2016 to focus on healthcare. The collaboration with Philips comes shortly after ANGLE's announcement of its co-marketing agreement with QIAGEN and is part of ANGLE's strategy to establish partnerships with a wide range of large companies for the commercialisation of ParsortixTM. In the year to 31 December 2016, of Philips' total revenues of €24.5 billion, €17.5 billion came from healthcare, which is their focus for future growth. The collaboration is planned for a four year period. It is estimated that grant funding of £0.1 million and £0.2 million will be received by ANGLE in the financial years ending 30 April 2018 and 2019, respectively. The remaining £0.1 million will spread over the following three financial years. ANGLE Founder and Chief Executive, Andrew Newland, commented: "We are delighted to be working with Philips and the other commercial partners on the development of new liquid biopsy solutions. We look forward to joint commercialisation of these solutions and to working closely with Philips going forward. This is a further demonstration of ANGLE's strategy to partner with large corporates to deliver widespread adoption of ANGLE's ParsortixTM CTC harvesting system." The press release issued by Philips today is reproduced in full below. PHILIPS Press Information November 23, 2017 Philips-led research consortium awarded EUR 6.3 million EU grant to develop integrated approaches for personalized cancer treatment · Four-year research project aims to increase accuracy of both genetic and functional characterization of primary breast and rectal cancer · Clinical research studies to be carried out at University Medical Center Utrecht (the Netherlands) and the Institut National de la Sante et de la Recherche Medicale (France) Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, together with its consortium partners, today announced that it has been awarded a EUR 6.3 million Horizon 2020 EU research grant to develop an integrated approach for personalized cancer treatment. The four-year research project, 'Liquid biopsies and IMAging for improved cancer care' (LIMA), aims to increase the accuracy of both genetic and functional characterization of primary breast cancer and rectal cancer by combining two diagnostic technologies: advanced blood tests called liquid biopsy and Magnetic Resonance Imaging (MRI). The clinical research studies will be carried out at the University Medical Center Universitair Medisch Centrum Utrecht in the Netherlands, and the Institut National de la Sante et de la Recherche Medicale in France. Integrating personalized treatment into the clinical workflow Each patient and tumor is unique, and often a treatment that's effective for one patient will be ineffective for another. The LIMA project aims to develop and validate tools and techniques that can be applied during the early stages of cancer treatment. This may enable clinicians to better understand the effectiveness of their approach, and to potentially adapt further steps in the individual treatment of the patient. Liquid biopsies, advanced laboratory analysis based on routinely drawn blood samples, support diagnosis by providing in-depth genetic information about tumors and metastases in the body. The analysis can be based on circulating tumor DNA (ct-DNA) or Circulating Tumor Cells (CTC) contained in the blood samples. MRI gives physicians information about the location of the cancer and functional information about the tumor tissue composition. For example, diffusion weighted MRI and perfusion MRI, well-known imaging biomarkers in oncology, will be further developed for tumor detection and characterization in order to provide comprehensive and quantitative information for an integral diagnostic approach. In addition, properties of MRI contrast at and around the tumor will be analyzed to shed light on the tumor grade and biological status, a field of imaging sciences called 'radiomics'. "In collaboration with our partners we will combine a range of liquid biopsy technologies, which give us more detailed molecular information, with advanced MRI techniques, which could enable us to better understand the impact of treatment at an early stage," said Hans Hofstraat, innovation program manager, Philips. "This has the potential to improve patient outcomes and potentially represents a significant step forward in delivering personalized cancer treatment." "With liquid biopsies we can analyze circulating tumor DNA and tumor cells in cancer that's advanced in a specific part of the body," said Alain Thierry, Research Director, at the Institut National de la Santé et de la Recherche Medicale (INSERM), Montpellier, France. "This technique is an important emerging field in diagnostics, particularly in oncology, and is starting to have a positive impact on patient care." "This project will allow us to build methods to look inside the body in much more detail, which has the potential to improve the treatment we provide and make a significant positive impact on the lives of our patients," said Kenneth Gilhuijs, associate professor and research coordinator at University Medical Center (UMC) Utrecht, the Netherlands. "By understanding the impact of treatment at an early stage, we will be able to deliver more targeted and effective therapy." Alongside Philips, INSERM and UMC Utrecht, the project involves several SMEs that have developed innovative technologies for liquid biopsies: Agena Bioscience GmbH (Germany), DiaDx (France) and Stilla Technologies (France) provide technologies for analyzing ct-DNA, ANGLE plc (UK) for CTC isolation and ALS Automation Lab Solutions GmbH (Germany) for single CTC detection and selection." Horizon 2020 is the largest-ever EU Research and Innovation program, with the goal of ensuring Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation. For further information, please contact: Mark Groves Philips Innovation & Strategy Tel.: +31 631 639 916 E-mail: mark.grove@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 73,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
mikepompeyfan
22/11/2017
20:58
I am trying to figure out why with the plentiful good news the share price behaves as it does. Institutions bought in the Oct 2017 35p placing, which was lower than the May 2016 64.5p placing. Edison's target Feb 2017 was 188p based on the ovarian studies. I wonder if indeed the ovarian results will be the trigger, to get the due recognition, of Parsortix, in 2018.
4legs
22/11/2017
19:49
I assumed increased target was simply to reflect funding and acquisition but haven't actually read research note. Has anyone?
bermudashorts
22/11/2017
19:33
It would be good to know if there is any news we don't already know, that prompted institutional investors to add in the placing and finnCap to put out its target.
4legs
22/11/2017
19:14
Anyone going to the Shares/AJ Bell presentations on Tuesday at the Novotel, featuring Angle
robow
22/11/2017
19:10
It would be good to get into the outer rings of the target.
semper vigilans
22/11/2017
19:08
Yes, looks like they increased it on 23rd Oct.
bermudashorts
Chat Pages: 1895  1894  1893  1892  1891  1890  1889  1888  1887  1886  1885  1884  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20171124 13:20:36